Description
Gabexate displays anticancer chemotherapeutic, anti-angiogenic, anti-inflammatory, and antiviral activities. In vitro, gabexate inhibits the activation of NF-κB, ERK1/2, and Akt, downregulates the production of matrix metalloproteinases 2 and 9, VEGF, and IL-8, and increases expression of protein and phosphatase and tensin homolog (PTEN). Gabexate acts as a proteasome inhibitor, inhibiting activity of tumor-associated trypsinogen and urokinase-type plasminogen activator and decreasing the invasiveness of pancreatic cancer cells. Additionally, gabexate inhibits production of TNF-α, preventing activation of MAPK signaling cascades in vitro. This compound also exhibits antiviral activity against the influenza virus, inhibiting cleavage of hemagglutinin.
References
Brandi G, Tavolari S, Guarnieri T, et al. Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. Pancreas. 2014 Jan;43(1):53-63. PMID: 24201777.
Hsieh HP, Hsu JT. Strategies of development of antiviral agents directed against influenza virus replication. Curr Pharm Des. 2007;13(34):3531-42. PMID: 18220789.
Uchima Y, Sawada T, Nishihara T, et al. Inhibition and mechanism of action of a protease inhibitor in human pancreatic cancer cells. Pancreas. 2004 Aug;29(2):123-31. PMID: 15257104.
Yuksel M, Okajima K, Uchiba M, et al. Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappaB and activator protein-1 in human monocytes. J Pharmacol Exp Ther. 2003 Apr;305(1):298-305. PMID: 12649382.
Aosasa S, Ono S, Mochizuki H, et al. Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor alpha production of monocytes. Shock. 2001 Feb;15(2):101-5. PMID: 11220636.
